Clinical Trial Results TV
April 19, 2006: The CHARISMA Trial: Implications For Your Practice
This video is sponsored by the Duke Clinical Medical Series.

Topics include:
* Clinical Case
* Medical History
* Laboratory Values
* Physical Examination
* Questions
* The CHARISMA Trial: Implications for Clinical Practice
* CAPRIE: Superior Efficacy of Clopidogrel vs ASA
* CAPRIE: Clopidogrel Reduced Rate of Rehosp
* Clopidogrel: Amplified Benefit Patients with High Vascular Risk

The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.

The guest, Deepak Bhatt, MD, has indicated that he is a consultant for Astra Zeneca,
Bristol-Myers Squibb, Eli Lilly, Millenium, Schering Plough, Sanofi Aventis, The Medicines

The CHARISMA Trial: Implications For Your Practice

Please select your viewing options:

Windows Media: 56k 100k
RealPlayer: 56k 100k
Number Viewing:
Need a media player? Please choose one of the free downloads below:
Get Windows Media PlayerDownload RealPlayer

Video Statistics
0 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 0 total votes.

These statistics are updated nightly. The last update ran on
10-18-2021 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted